Organon & Co. - Understand $ogn stock

$OGN Market Cap: $3.956 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$6.409B

TTM

Gross Margin

58.52%

TTM

Net Earnings

$1.301B

TTM

Current Assets

$4.756B

Q3 2024

Current Liabilities

$2.790B

Q3 2024

Current Ratio

170.47%

Q3 2024

Total Assets

$12.75B

Q3 2024

Total Liabilities

$12.26B

Q3 2024

Book Value

$493.0M

Q3 2024

Cash

$763.0M

Q3 2024

P/E

3.041

Nov 29, 2024 EST

Free Cash Flow

$698.0M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$6.263B	$6.174B	$6.304B	$6.532B	$7.777B	$9.777B	$10.50B
YoY Change	1.44%	-2.06%	-3.49%	-16.01%	-20.46%	-6.89%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$6.263B	$6.174B	$6.304B	$6.532B	$7.777B	$9.777B	$10.50B
Cost Of Revenue	$2.468B	$2.294B	$2.382B	$2.119B	$2.274B	$4.693B	$4.657B
Gross Profit	$3.795B	$3.880B	$3.922B	$4.413B	$5.503B	$5.084B	$5.843B
Gross Profit Margin	60.59%	62.84%	62.21%	67.56%	70.76%	52.0%	55.65%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	$1.715B	$1.704B	$1.668B	$1.356B	$1.443B	$2.013B	$2.285B
YoY Change	0.65%	2.16%	23.01%	-6.03%	-28.32%	-11.9%
% of Gross Profit	45.19%	43.92%	42.53%	30.73%	26.22%	39.59%	39.11%
Research & Development	$516.0M	$471.0M	$443.0M	$210.0M	$220.0M	$365.0M	$355.0M
YoY Change	9.55%	6.32%	110.95%	-4.55%	-39.73%	2.82%
% of Gross Profit	13.6%	12.14%	11.3%	4.76%	4.0%	7.18%	6.08%
Depreciation & Amortization	$120.0M	$96.00M	$92.00M	$56.00M	$49.00M	$1.673B	$1.973B
YoY Change	25.0%	4.35%	64.29%	14.29%	-97.07%	-15.21%
% of Gross Profit	3.16%	2.47%	2.35%	1.27%	0.89%	32.91%	33.77%
Operating Expenses	$2.229B	$2.175B	$2.111B	$1.566B	$1.663B	$2.191B	$2.583B
YoY Change	2.48%	3.03%	34.8%	-5.83%	-24.1%	-15.18%
Operating Profit	$1.566B	$1.705B	$1.811B	$2.847B	$3.840B	$2.893B	$3.260B
YoY Change	-8.15%	-5.85%	-36.39%	-25.86%	32.73%	-11.26%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017
Interest Expense	-$569.0M	$422.0M	$258.0M	$0.00	$0.00	-$45.00M	$21.00M
YoY Change	-234.83%	63.57%			-100.0%	-314.29%
% of Operating Profit	-36.33%	24.75%	14.25%	0.0%	0.0%	-1.56%	0.64%
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017
Pretax Income	$673.0M	$1.122B	$1.529B	$2.752B	$3.696B	$2.729B	$3.099B
YoY Change	-40.02%	-26.62%	-44.44%	-25.54%	35.43%	-11.94%
Income Tax	-$350.0M	$205.0M	$178.0M	$496.0M	$390.0M	$576.0M	$1.298B
% Of Pretax Income	-52.01%	18.27%	11.64%	18.02%	10.55%	21.11%	41.88%
Net Earnings	$1.023B	$917.0M	$1.351B	$2.160B	$3.218B	$2.153B	$1.801B
YoY Change	11.56%	-32.12%	-37.45%	-32.88%	49.47%	19.54%
Net Earnings / Revenue	16.33%	14.85%	21.43%	33.07%	41.38%	22.02%	17.15%
Basic Earnings Per Share	$4.01	$3.61	$5.33	$8.52	$12.69
Diluted Earnings Per Share	$3.99	$3.59	$5.31	$8.52	$12.69	$8.505M	$7.115M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018
Cash & Short-Term Investments	$693.0M	$706.0M	$737.0M	$12.00M	$319.0M	$244.0M
YoY Change	-1.84%	-4.21%	6041.67%	-96.24%	30.74%
Cash & Equivalents	$693.0M	$706.0M	$737.0M	$12.00M	$319.0M	$244.0M
Short-Term Investments
Other Short-Term Assets	$643.0M	$637.0M	$611.0M	$1.289B	$904.0M	$985.0M
YoY Change	0.94%	4.26%	-52.6%	42.59%	-8.22%
Inventory	$1.315B	$1.003B	$915.0M	$913.0M	$1.071B	$994.0M
Prepaid Expenses
Receivables	$1.744B	$1.475B	$1.382B	$1.038B	$1.474B	$1.491B
Other Receivables	$113.0M	$110.0M	$115.0M	$315.0M	$187.0M	$0.00
Total Short-Term Assets	$4.508B	$3.931B	$3.760B	$3.567B	$3.955B	$3.714B
YoY Change	14.68%	4.55%	5.41%	-9.81%	6.49%
Property, Plant & Equipment	$1.356B	$1.233B	$1.203B	$1.015B	$762.0M	$651.0M
YoY Change	9.98%	2.49%	18.52%	33.2%	17.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.058B	$539.0M	$464.0M	$421.0M	$659.0M	$714.0M
YoY Change	96.29%	16.16%	10.21%	-36.12%	-7.7%
Total Long-Term Assets	$7.550B	$7.024B	$6.921B	$6.542B	$6.593B	$6.780B
YoY Change	7.49%	1.49%	5.79%	-0.77%	-2.76%
Total Assets	$12.06B	$10.96B	$10.68B	$10.11B	$10.55B	$10.49B
YoY Change
Accounts Payable	$1.314B	$1.132B	$1.382B	$259.0M	$258.0M	$289.0M
YoY Change	16.08%	-18.09%	433.59%	0.39%	-10.73%
Accrued Expenses	$1.389B	$1.188B	$1.021B	$659.0M	$807.0M	$819.0M
YoY Change	16.92%	16.36%	54.93%	-18.34%	-1.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$1.339B	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$9.000M	$8.000M	$9.000M	$0.00
YoY Change	12.5%	-11.11%
Total Short-Term Liabilities	$2.918B	$2.512B	$2.597B	$2.673B	$1.341B	$1.545B
YoY Change	16.16%	-3.27%	-2.84%	99.33%	-13.2%
Long-Term Debt	$8.751B	$8.905B	$9.125B	$0.00	$70.00M	$34.00M
YoY Change	-1.73%	-2.41%		-100.0%	105.88%
Other Long-Term Liabilities	$412.0M	$411.0M	$463.0M	$1.822B	$1.963B	$2.418B
YoY Change	0.24%	-11.23%	-74.59%	-7.18%	-18.82%
Total Long-Term Liabilities	$9.163B	$9.316B	$9.588B	$1.822B	$2.033B	$2.452B
YoY Change	-1.64%	-2.84%	426.23%	-10.38%	-17.09%
Total Liabilities	$12.13B	$11.85B	$12.19B	$4.623B	$3.513B	$4.146B
YoY Change	2.37%	-2.81%	163.66%	31.6%	-15.27%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	255.2M shares	254.1M shares	253.5M shares	253.5M shares	253.5M shares
Diluted Shares Outstanding	256.3M shares	255.2M shares	254.2M shares	253.5M shares	253.5M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $3.9558 Billion

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.

Industry: Pharmaceutical Preparations Peers: BRISTOL MYERS SQUIBB CO Catalent, Inc. CORCEPT THERAPEUTICS INC Elanco Animal Health Inc Intra-Cellular Therapies, Inc. JOHNSON & JOHNSON Royalty Pharma plc Viatris Inc Zoetis Inc.